Becton, Dickinson and Company (BDX)
After hours:
| Previous close | 232.78 |
| Open | 234.78 |
| Bid | 230.00 x 800 |
| Ask | 242.99 x 1200 |
| Day's range | 232.38 - 239.22 |
| 52-week range | 218.75 - 285.49 |
| Volume | |
| Avg. volume | 1,512,337 |
| Market cap | 68.581B |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 50.71 |
| EPS (TTM) | 4.68 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | 3.80 (1.63%) |
| Ex-dividend date | 09 Sept 2024 |
| 1y target est | 275.33 |
PR NewswireBD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a global collaboration agreement to develop, manufacture and commercialize flow cytometry-based companion diagnostics (CDx) intended to help select the best treatment for patients with cancer and other diseases.
ZacksReasons to Add The Cooper Companies (COO) to Your Portfolio Now
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
PR NewswireBD Board Declares Dividend
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share.
